Interested working with us
WHY CHOOSE KEXING
Kexing Biopharm (Stock Code: 688136.SH) is a leading multinational biopharmaceutical company specializing in the research, manufacture, and commercialization of innovative medicines combining recombinant proteins, antibodies, and targeted delivery therapies, etc. Harnessing proprietary technology platforms, Kexing pioneers novel targeted biological therapies and advanced drug delivery systems to address critical unmet needs in oncology, autoimmune and infectious diseases, making transformative impact on patients.Driven by a dual strategic focus on breakthrough innovation and global outreach, Kexing is committed to becoming a world-class leader in bringing high-quality pharmaceutical solutions to patients worldwide.
Kexing Biopharm offers a diversified portfolio of more than 30 innovative products, including drugs "Human Erythropoietin Injection (EPOSINO)", "Human Interferon α1b for Injection (SINOGEN)" and "Human Granulocyte Colony-stimulating Factor Injection (WHITE-C)"; microecological agents, notably "Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO)"; targeted drugs, such as "Albumin-bound Paclitaxel (Apexelsin)" and "Infliximab for Injection (Reminton)". Our core products outperform competitors' options in China, with SINOGEN and EPOSINO leading positions in their respective therapeutic categories. Our products are supplied to over 20,000 sales terminals across China. In addition, we have established 6 overseas subsidiaries, which have acquired market access and achieved sales in over 70 countries and regions such as the European Union, Brazil, Philippines and Indonesia. In recent years, we also have created a high-quality biopharmaceuticals overseas platform based on the concept of "Global Product Selection + Global Product Coverage", and secured commercial partnerships with numerous renowned pharmaceutical companies worldwide by leveraging its global marketing infrastructure, targeted market penetration strategies, and commitment to delivering premium-quality products and services.
Kexing Biopharm operates multiple R&D centers, such as the Shenzhen Medical Research Institute, the Shandong R&D Center and the Guangzhou R&D Center. It boasts an R&D team of nearly 200 members, with over 60% holding master's degrees or higher. At present, it has obtained 72 patents. It has built several leading technology platforms worldwide, such as KX-FUSION recombinant protein therapeutics technology platform, KX-BODY antibody technology platform, K'Exosome drug delivery technology platform, Probiotic agent R&D and industrialization platform, and Vector vaccine technology platform.
The Company focuses on biopharmaceuticals and implements a strategic R&D plan that enables a tiered, serial, and graduated product portfolio. Our short-term efforts are concentrated on in-depth development around new formulations, new indications and long-acting effects for recombinant protein therapeutics. In the medium and long term, we focus on fields such as oncology, immunology and degenerative diseases, with plans to develop new antibodies, proteins and etc. It boasts robust pipelines of innovative drugs and dozens of projects currently under development, including GB05 Human Interferon α1b Inhalation Solution (Phase III clinical trial), GB-K02 Long-acting Human Granulocyte Colony-stimulating Factor Injection (Phase III clinical trial), GB08 Long-acting Growth Hormone, GB10 (target: VEGF/ANG-2) for fundus diseases, GB18 (target: GDF-15) for cancer cachexia, GB19/GN26 for lupus erythematosus, GB23 (target: IFN/GPC3/PD1) for solid tumors, GB24 (target: TL1A, bispecific antibody) for inflammatory bowel diseases, and GB25 (tri-specific antibody) for colorectal cancer.
Following the mission of "Precise Products, Predictable Effects, Health Protection", we are devoted to providing patients with biotechnology and becoming the leader in high-quality biologics!
